These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 10029430)

  • 1. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
    Feldkamp MM; Angelov L; Guha A
    Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.
    Guha A; Lau N; Huvar I; Gutmann D; Provias J; Pawson T; Boss G
    Oncogene; 1996 Feb; 12(3):507-13. PubMed ID: 8637706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofibromatosis type 1: piecing the puzzle together.
    Feldkamp MM; Gutmann DH; Guha A
    Can J Neurol Sci; 1998 Aug; 25(3):181-91. PubMed ID: 9706718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characterization of the neurofibromatosis type 1 gene and neurofibromin's role in cells].
    Sakai A
    Nihon Rinsho; 2000 Jul; 58(7):1426-9. PubMed ID: 10921317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
    Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
    J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From gene to disease; neurofibromatosis type 1].
    de Goede-Bolder A; Cnossen MH; Dooijes D; van den Ouweland AM; Niermeijer MF
    Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1736-8. PubMed ID: 11572174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
    Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras-GTP regulation is not altered in cultured melanocytes with reduced levels of neurofibromin derived from patients with neurofibromatosis 1 (NF1).
    Griesser J; Kaufmann D; Eisenbarth I; Bäuerle C; Krone W
    Biol Chem Hoppe Seyler; 1995 Feb; 376(2):91-101. PubMed ID: 7794530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapeutic targets for neurofibromatosis type 1.
    Walker JA; Upadhyaya M
    Expert Opin Ther Targets; 2018 May; 22(5):419-437. PubMed ID: 29667529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in the neurofibromatosis 1 gene in human tumors.
    Li Y; Bollag G; Clark R; Stevens J; Conroy L; Fults D; Ward K; Friedman E; Samowitz W; Robertson M
    Cell; 1992 Apr; 69(2):275-81. PubMed ID: 1568247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular genetics of neurofibromatosis type 1].
    Suzuki H; Takahashi K; Shibahara S
    Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-targeted deletion of neurofibromin enhances the expression of a transient outward K+ current in Schwann cells: a protein kinase A-mediated mechanism.
    Xu Y; Chiamvimonvat N; Vázquez AE; Akunuru S; Ratner N; Yamoah EN
    J Neurosci; 2002 Nov; 22(21):9194-202. PubMed ID: 12417644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.